tirzepatide black friday deals Compounded With B6 (Pyridoxine) Did you hear the news?

The decrease of total and primary BAs and the increase of fecal lithocholic acid are significant predictors of stool weight, frequency, and consistency

Cell 108 , 279293 (2016)

Semaglutide is a GLP-1 agonist that is FDA approved for the treatment of type 2 diabetes and weight loss

and stock options from Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego and Stability Health

What we now have, in the same class, for HFpEF + obesity: Semaglutide (STEP-HFpEF and STEP-HFpEF DM): symptom and physical-limitation benefit Tirzepatide (SUMMIT, NEJM 2025): symptom benefit plus a reduction in CV death and worsening HF events (the morbidity-mortality data) The ACC 2025 Scientific Statement endorsing GLP-1 / GIP agonists as part of HF care in obesity Three things this does to clinical thinking: Obesity-related HFpEF is no longer best framed as "HF the cardiologist treats and obesity the primary care doctor treats." It is one disease with two phenotypes, and increasingly one therapy

Ensure that all syringes and needles are sterile before use